Gene-environment interaction analysis in atopic eczema: evidence from large population datasets and modelling *in vitro*.

Marie Standl[1,2]*, Ashley Budu-Aggrey[3]*, Luke J Johnston[4], Martina S Elias[4], S Hasan Arshad[5,6,7], Peter Bager[8], Veronique Bataille[9], Helena Blakeway[3], Klaus Bonnelykke[10], Dorret Boomsma[11], Ben M Brumpton[12], Mariona Bustamante Pineda[13,14,15], Archie Campbell[4], John A Curtin[16], Anders Eliasen[10], João PS Fadista[8], Bjarke Feenstra[8], Trine Gerner[17], Carolina Medina Gomez[18], Sarah Grosche[19], Kristine B. Gutzkow[20], Anne-Sofie Halling[21], Caroline Hayward[4], John Henderson[3], Esther Herrera-Luis[22], John W Holloway[6,23], Joukejan Hottenga[11], Jonathan O'B Hourihane[24,25.26], Chen Hu[27,28], Kristian Hveem[12,29], Amaia Irizar[15,30,31], Benedicte Jacquemi[32], Leon Jessen[10], Sara Kress[33], Ramesh J Kurukulaaratchy[5,6,7], Susanne Lau[34], Sabrina Llop[15,35], Mari Løset[12,36], Ingo Marenholtz[19,37], Dan Mason[38], Daniel L McCartney[4], Mads Melbye[39,40,41], Erik Melén[42], Camelia Minica[11], Clare S Murray[16], Tamar Nijsten[28], Luba M Pardo[28], Suzanne Pasmans[28], Craig E Pennell[43,44], Maria R Rinnov[17,45], Gillian Santorelli[38], Tamara Schikowski[33], Darina Sheehan[26,46,47], Angela Simpson[16], Cilla Söderhäll[48], Laurent F Thomas[12,49,50], Jacob P Thyssen[21], Maties Torrent[51], Toos van Beijsterveldt[11], Alessia Visconti [9,52], Judith M. Vonk[53,54], Carol A Wang[43,44], Cheng-Jian Xu[55,56], Ali H Ziyab[57], UK-Translational Research Network in Dermatology, BIOMAP consortium, Adnan Custovic[58], Paola Di Meglio[59,60], Liesbeth Duijts[61,62], Carsten Flohr[63], Alan D Irvine[64], Gerard H Koppelman[54,65], Young-Ae Lee[19,34,37], Nick J Reynolds[66,67], Catherine Smith[60], Sinéad M Langan[68,69]*, Lavinia Paternoster[3,70]* and Sara J Brown[4,71]*[§].

*authors contributed equally

[§]corresponding author

Affiliations

1. Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.

2. German Center for Child and Adolescent Health (DZKJ), partner site Munich, Munich, Germany.

3. MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, UK.

4. Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, Crewe Road South, University of Edinburgh, Edinburgh, UK.

5. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

6. NIHR Southampton Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

7. Asthma and Allergy Research Centre, Isle of Wight, UK.

8. Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.

9. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.

10. COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.

11. Vrije Universiteit, Department of Biological Psychology Van der Boechorststraat, Amsterdam, The Netherlands.

12. HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.

13. ISGlobal, Institute for Global Health, Barcelona, Spain.

14. Universitat Pompeu Fabra (UPF), Barcelona, Spain.

15. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.

45 16. Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The
46 University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS
47 Foundation Trust, Manchester, United Kingdom.

48 17. Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen,
49 Hellerup, Denmark.

50 18. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam,
51 The Netherlands.

52 19. Max-Delbrück-Center (MDC) for Molecular Medicine, 13125, Berlin, Germany.

53 20. Department of Air Quality and Noise, Division of Climate and Environmental Health, Norwegian Institute of
54 Public Health (NIPH), Oslo, Norway.

55 21. Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Bispebjerg
56 Bakke 23, build. 4, 2400 Copenhagen N, Denmark.

57 22. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, *MD*
58 *21205, USA.*

59 23. Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.

60 24. Royal College of Surgeons in Ireland, Dublin, Ireland.

61 25. Children's Health Ireland, Dublin, Ireland.

62 26. INFANT Centre, University College Cork, Cork, Ireland.

63 27. The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
64 Netherlands.

65 28. Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
66 Netherlands.

67 29. Department for Research, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.

68 30. Department of Preventive Medicine and Public health, UPV/EHU, Spain.

31. Biogipuzkoa HRI, Donostia, Spain.

32. Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

33. IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.

34. Department of Pediatric Respiratory Medicine, Immunology, and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.

35. Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I–Universitat de València, Valencia, Spain.

36. Department of Dermatology, Clinic of Orthopedy, Rheumatology and Dermatology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.

37. Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité University Medical Center, Berlin, Germany.

38. Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, England, BD9 6RJ, UK.

39. Danish Cancer Institute, Copenhagen, Denmark.

40. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

41. Department of Pediatrics, Stanford University School of Medicine, Stanford, USA.

42. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.

43. School of Medicine and Public Health, The University of Newcastle, New South Wales, NSW 2308, Australia.

44. Mothers and Babies Research Program, Hunter Medical Research Institute, New South Wales, NSW 2305, Australia.

45. Department of Neonatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

46. University College Cork, College Road, Cork, Ireland.

47. Cork University Hospital, Wilton, Cork, Ireland.

48. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

49. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

50. BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway.

51. Area de Salut de Menorca, ib-salut, Balearic Islands, Spain.

52. Center for Biostatistics, Epidemiology and Public Health, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

53. University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.

54. University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, The Netherlands.

55. Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH). Hannover, Germany.

56. TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.

57. Department of Community Medicine and Behavioral Sciences, College of Medicine, Kuwait University, Kuwait.

58. National Heart and Lung Institute, Imperial College London, UK.

59. The Francis Crick Institute, London, UK.

60. St John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London.

61. Department of Pediatrics, divisions of Respiratory Medicine and Allergology, and Neonatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

117 62. Department of Neonatal and Intensive Care, division of Neonatology, Erasmus MC, University Medical
118 Center Rotterdam, Rotterdam, The Netherlands.

119 63. Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS
120 Foundation Trust and King's College London, London, UK.

121 64. Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.

122 65. University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of
123 Pediatric Pulmonology and Pediatric Allergology, Groningen, The Netherlands.

124 66. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle
125 upon Tyne, UK.

126 67. Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne
127 Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

128 68. Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London,
129 UK.

130 69. St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

131 70. NIHR Bristol Biomedical Research Centre, University Hospital Bristol and Weston NHS Foundation Trust and
132 University of Bristol, Bristol, UK.

133 71. Department of Dermatology, NHS Lothian, Lauriston Building, Edinburgh, Scotland, UK.

Abstract

Background

Environmental factors play a role in the pathogenesis of complex traits including atopic eczema (AE) and a greater understanding of gene-environment interactions (G*E) is needed to define pathomechanisms for disease prevention. We analysed data from 16 European studies to test for interaction between the 24 most significant AE-associated loci identified from genome-wide association studies and 18 early-life environmental factors. We tested for replication using a further 10 studies and *in vitro* modelling to independently assess findings.

Results

The discovery analysis showed suggestive evidence for interaction ($p<0.05$) between 7 environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking and washing practices) and at least one established variant for AE, 14 interactions in total (maxN=25,339). In replication analysis (maxN=252,040) dog exposure*rs10214237 (on chromosome 5p13.2 near *IL7R*) was nominally significant ($OR_{interaction}$=0.91 [0.83-0.99] P=0.025), with a risk effect of the T allele observed only in those not exposed to dogs. A similar interaction with rs10214237 was observed for siblings in the discovery analysis ($OR_{interaction}$=0.84[0.75-0.94] P=0.003), but replication analysis was under-powered $OR_{interaction}$=1.09[0.82-1.46]). Rs10214237 homozygous risk genotype is associated with lower IL-7R expression in human keratinocytes, and dog exposure modelled *in vitro* showed a differential response according to rs10214237 genotype.

Conclusions

Interaction analysis and functional assessment provide evidence that early-life dog exposure may modify the genetic effect of rs10214237 on AE via *IL7R*, supporting observational epidemiology showing a protective effect for dog ownership. The lack of evidence for other G*E studied here implies that only weak effects are likely to occur.

Key words

Atopic eczema; atopic dermatitis; genetic; environment; interaction; epidemiology; dog; sibling

Background

Atopic eczema (AE, synonymous with atopic dermatitis or eczema [1]) is a chronic inflammatory skin and systemic condition affecting approximately 20% of children and 10% of adults in high-income countries. Eczema is the dermatosis which contributes the greatest number of disability-adjusted life years worldwide [2] and co-morbid conditions, including asthma and allergies, obesity, cardiovascular disease, anxiety and depression add substantially to the social, academic, occupational, and financial impact [3]. Atopic eczema is a heritable trait [4] but the rapid rise in prevalence in industrialised areas over the past 30 years [3, 5] illustrates the importance of environmental factors in aetiology. A greater understanding of environmental effects in driving pathology could facilitate disease prevention.

The European Academy of Allergy and Clinical Immunology published an umbrella review of systematic reviews in allergy epidemiology and identified a relative lack of research in eczema genetic epidemiology and environmental effects [6]. The investigation of environmental factors using observational epidemiology is inherently challenging in the context of AE because there are multiple confounding factors and possible reverse causation [7]. Genetic studies, however, have made substantial progress in defining mechanisms in eczema predisposition and pathogenesis, including skin barrier dysfunction and aberrant immune response [8]. The evidence of individual variation in susceptibility to environmental allergens and irritants supports the concept of gene-environment interaction (G*E) [9] playing a role in AE and loss-of-function variants in *FLG* encoding the skin barrier protein filaggrin have been implicated [10]. Knowledge of genetic risk may therefore provide an opportunity to identify key environmental effects and clarify important disease biology.

182 We aimed to investigate evidence of interaction between the most highly significant eczema risk loci
183 defined by genome-wide association studies [11] and environmental risk factors selected based on
184 previous literature [7, 10] and importance to patients and carers [12]. We used early-life
185 environmental exposures (*in utero* and up to the first 12 months of life) to minimise reverse
186 causation and focus on disease pathogenesis. G*E was tested in cohorts and data from European
187 populations, in discovery and replication phases as a pragmatic approach to maximise sample size.
188 Mechanistic assessment was carried out *in vitro* in a skin keratinocyte model to validate the observed
189 interactions.

190

191 **Results**

192 Analysis was conducted to assess observational association (of environmental effects) followed by
193 interaction effect (of environmental and genetic risk factors) in the discovery cohorts; next the
194 nominally significant findings and those with *a priori* evidence were tested for replication in available
195 larger cohorts.

196 ***Discovery analysis***

197 In meta-analyses of between 1,084 and 22,263 participants (dependent on exposure, **Additional file**
198 **1**) we found strong evidence for antibiotic use increasing risk of AE (*in utero* p=0.004, at 6 months
199 p=0.001 and at 12 months $p=6x10^{-4}$); weaker evidence was found for a protective effect of dog
200 ownership (p=0.03), protective effect of childhood smoke exposure (p=0.038) and risk effect of NO_2
201 levels (p=0.035) (M1 models, **Additional file 2**). Little evidence (p>0.05) was found for main effects of
202 caesarean delivery, cat ownership, breastfeeding, elder siblings, *in utero* smoke exposure, washing
203 practices at 6 months and 2 years, PM10 exposure and house dust mite exposure at birth or 1 year
204 (M1 models, **Additional file 2**).

205 Of the 432 interactions tested (between 24 genetic variants and 18 environmental exposures), we
206 found no significant interactions that passed multiple testing correction, yet 14 nominally significant
207 (p_{int}<0.05) interactions (**Figure 1, Table 1**). Of these, 8 interactions indicated a higher genetic risk in
208 the presence of the exposure (OR > 1) and 6 indicated a higher genetic risk in the unexposed stratum
209 (OR < 1). Of the 18 environmental exposures tested, the two with the strongest evidence for
210 interaction with *FLG* null variants were exposure to tobacco smoke between 0 and 2 years
211 (p_{int}=0.018) and washing practices during the same period (p_{int}=0.045). There was little evidence
212 (p>0.05) for interactions between *FLG* null variants and other tested exposures, though confidence
213 intervals for some interaction estimates were wide (**Additional file 2**). Notably, there was little
214 evidence for interaction between *FLG* null variants and cat exposure (p=0.36), with strong effects of
215 *FLG* in both the unexposed and exposed strata.

216 Sensitivity analyses, additionally adjusting for family history of AE and socioeconomic status, broadly
217 supported the results of the main analyses (**Additional file 2**), but many of the sensitivity analyses
218 are based on much smaller sample sizes because of the requirement for data on additional
219 covariates. There was little evidence of heterogeneity between cohorts (smallest $p_{het=}$0.01) amongst
220 the 14 reported interactions.

221 ***Replication analysis***

222 We took the 14 interactions with nominal evidence forward to replication, but also the exposures
223 that had prior literature suggesting an interaction with *FLG* null variants (cat, siblings and breast-
224 feeding [10]). In total, 19 interactions based on 8 different exposures and 10 genetic variants were
225 included in the replication.

226 In replication analysis dog exposure and rs1041237 showed evidence for interaction (p=0.025), **Table**
227 **1**. In an analysis stratified by dog exposure the T allele increases risk of atopic eczema (OR=1.14, 95%
228 CI 1.08 to 1.22), but only amongst those who are not exposed to a dog in the family home. In

229 individuals who are exposed to dog in early life, this variant appears to have little effect (OR=0.98,
230 95% CI 0.68-1.11 **Figure 2**).

231 Availability of environmental data for replication varied, with many of our attempted replications of
232 interactions being insufficiently powered to be conclusive. Washing practices (0-2y) and antibiotic
233 use *in utero* interactions had only 3 and 4% power respectively (given the interaction effects
234 observed in the discovery phase, **Additional file 3**). The tobacco exposure in utero interaction only
235 reached 11% power and the four sibling interactions had between 8 and 37% power (dependent on
236 variant). The breast-feeding duration interaction only had 4% power in the replication phase and so
237 we extended the replication analysis to 'ever breastfed' to increase the power to 56%. The
238 interactions with dog, cat and tobacco smoke exposure 0-2 years were all sufficiently powered (88%,
239 72-88% and 99%, respectively, **Additional file 3**). The previously reported interactions between *FLG*
240 null mutations and cat, siblings and ever breastfed had 99% power given their reported interaction
241 effects (**Additional file 3**).

242 ***In silico* follow-up of rs10214237*dog interaction**

243 Rs10214237 is an intergenic variant (T>C) on chromosome 5p13.2; this was identified in association
244 with eczema by a genome-wide association study (GWAS) [11] in which *IL7R* was prioritised as the
245 likely causal gene based on evidence including eQTL colocalisation in macrophages and monocytes
246 [13, 14]. The top single nucleotide variant (SNV) at this locus in more recent meta-analysis [13] is
247 rs10214273, but this variant is in complete linkage disequilibrium with rs10214237 in European
248 populations (R^2=1, LDLink version 5.6.6, LDPair tool). Global population data from gnomAD shows
249 ancestral difference in allele frequency, with rs10214237 being more frequent in European and South
250 Asian populations (MAF 0.28 and 0.20 respectively) compared to African people (MAF 0.07) (1KG
251 data accessed 10 Jan 2025).

252 Rs10214237 is within a region of open chromatin in keratinocytes and fibroblasts, but not the
253 lymphoblastoid cell line GM12878 (UCSC Genome Browser 06 Feb and 27 Nov 2024). Open Targets

254 V2G analyses confirm *IL7R* as most likely gene affected by this SNV based on pQTL, sQTL and eQTL
255 (06 Feb and 27 Nov 2024). GTEx data show that expression of *IL7R* is higher with T:T genotype in
256 whole blood and cultured fibroblasts and in newly generated data we show that individuals with the
257 T:T genotype have slightly higher *IL7R* mRNA expression in primary human keratinocytes than those
258 with the C:C genotype (**Additional file 4**). Single cell data from the Human Protein Atlas [15, 16]
259 confirms that IL-7R is expressed at protein level in human keratinocytes, in addition to circulating
260 immune cells.

261 ***In vitro* testing of the effects of dog allergen on human keratinocytes**

262 Human keratinocytes comprise the outermost layer of skin and can therefore represent the first line
263 of interaction in an allergen encounter *in utero* or early life. To further investigate the effect of dog
264 exposure in early life, primary normal human keratinocytes were exposed to clinical-grade dog
265 epithelial extract, a standardised reagent used for allergy testing in the clinic [17]. Dog allergen
266 exposure stimulated an up-regulation in *CXCL8* (IL-8), *CSF2*, *CCL2* and *TNF* mRNA but the atopy-
267 related cytokines *IL33* and *TSLP* mRNA were down-regulated (**Figure 3A**). Network analysis of the
268 proteins encoded by the upregulated transcripts showed significant enrichment for IL-10 signalling
269 (**Figure 3B**, Reactome pathway FDR 7.71e-08) which plays a suppressive role in contact dermatitis
270 and atopic eczema [18]. To test the keratinocyte response more broadly, we used an ELISA panel of
271 64 cytokine, chemokines and receptors (**Additional file 5**). This confirmed the signature of increased
272 IL-10 signalling (**Additional file 5**).

273 Next, using primary human keratinocytes of known rs10214237 genotype and focusing on CXCL8 (IL-
274 8), CCL2 and IL-6 as molecules of relevance to IL-7R signalling in epithelial cells, we investigated the
275 effect of dog allergen exposure, with and without IL-7 stimulation (**Figure 3C-E**). There was no
276 difference in expression levels after IL-7 stimulation, but on stimulation with dog extract (or IL-7 plus
277 dog extract), keratinocytes of T:T genotype (homozygous for the eczema-risk allele) showed a greater
278 response than the C:C genotype.

279 Together these observations provide a possible mechanistic explanation for the finding that the T
280 allele at rs10214237 increases risk for atopic eczema; the T:T genotype shows greater IL-7R mRNA
281 expression, but in the context of dog exposure the risk effect is overshadowed by an increase in
282 cytokines and chemokines in the IL-10 pathway which suppresses eczema to a greater extent in T:T
283 than C:C individuals.

284

285 **Discussion**

286 Our collaborative work represents the largest and most comprehensive analysis to date investigating
287 G*E in atopic eczema, using a systematic approach focussed on the most significant genetic loci and
288 selected environmental factors. We first meta-analysed data from available observational studies to
289 test for association and then applied interaction analysis to investigate G*E. Statistical power remains
290 a limiting factor and the nominal significance level ($p<0.05$ without correction for multiple testing)
291 means cautious interpretation is needed. We have identified important negative results as well as
292 one interaction with functional validation *in vitro* and others that warrant further follow up.

293 A variety of sources provide evidence that G*E plays a role in the aetiology of atopic eczema. These
294 include rapidly rising prevalence [5], clinical observation [4], epidemiological studies [10], and *in vitro*
295 analyses demonstrating molecular effects that include aryl hydrocarbon receptor signalling [19].
296 Some authors have even stated that 'atopic eczema is an environmental disease' [20]. Our meta-
297 analysis of observational associations provides evidence that early-life exposure to antibiotics and
298 NO_2 levels associate with increased risk of AE, whilst early-life exposure to dog or tobacco smoke is
299 associated with a lower risk of AE in the populations studied. However, these associations may be
300 affected by bias through confounding and reverse causation.

301 Statistical interaction analysis indicates that early-life dog exposure may modify the genetic effect of
302 rs10214237. Functional genetic analyses show an effect mediated via the gene *IL7R* which encodes
303 the alpha-subunit of the IL-7 receptor. Rs10214237 T:T genotype was associated with an increased

304 risk of atopic eczema in population as a whole and in the sub-population without dog exposure
305 (**Figure 2**) consistent with the T:T genotype showing greater IL7R mRNA expression (**Additional file**
306 **4**). The IL-7 receptor is a heterodimer composed of IL7R-alpha and IL2R-gamma. It is expressed is
307 multiple cell-types and tissues, including T-cells, NK-cells, glandular and stratified epithelial cells (data
308 from Human Protein Atlas [15, 16]). IL7R-alpha also contributes to a heteromeric complex with the
309 thymic stromal lymphopoietin (TSLP) receptor but our experimental work to test TSLP as an
310 alternative ligand in keratinocytes was not informative (data not shown) likely, in part, because the
311 TSLPR is only very lowly expressed in this cell type [21].

312 Our detailed *in vitro* work focussed on human epidermal keratinocytes as the earliest tissue to
313 encounter dog allergen in the initiation of atopic disease, *in utero* or early infancy. We have shown
314 that keratinocytes display a direct response to dog allergen exposure, with down-regulation of IL-33
315 and TSLP mRNA (both inducers of type 2 immune responses in atopy [22, 23]) and upregulation of a
316 network of genes encoding chemokines and cytokines of IL-10 signalling (Reactome pathway HAS-
317 6783783), contributing to the suppression of atopic inflammation [18]. This is consistent with
318 observational epidemiology showing an apparent protective effect of dog exposure early in life [24]
319 [25]. Gene ontology analysis of the same network indicates a role in cellular response to
320 lipopolysaccharide (GO:0071222), likely to reflect a response to gram negative components of the
321 canine microbiome.

322 The proposed interaction with genotype was investigated using keratinocytes of known rs10214237
323 status. Here the T:T genotype showed a greater increase in IL-10 signalling in response to dog
324 allergen exposure than the C:C genotype, which is consistent with the suppression of atopic eczema
325 risk on a population level in the dog-exposed T:T individuals, whilst non-dog-exposed T:T individuals
326 remain at risk of disease. The interaction is analogous to a 17q21*dog interaction demonstrated in
327 asthma [26] in which the risk of persistent wheeze is attenuated by dog ownership [26]. There is an
328 interesting parallel in the interaction of rs10214237 with exposure to older siblings, in which the
329 older sibling abrogates risk effect for rs10214237. We speculate that this may be related to the

330 increased microbial exposure experienced by an infant with older siblings (or a dog) in the
331 household, and there is evidence of shared skin and gut microbiome between humans and their
332 pets[27], but it could also reflect lifestyle choices of dog-owning families and these hypotheses
333 require further testing.

334 There are some limitations to this work. The discovery analysis used selected SNVs to represent
335 known eczema risk loci, rather than conducting a genome-wide interaction analysis. This restricted
336 approach has been shown to be effective in other traits [28]; it is needed because of power
337 constraints, even in large population datasets. A post-hoc estimation of statistical power (**Additional**
338 **file 3**) showed that our replication sample sizes were insufficient for some interactions. Therefore,
339 where replication results do not meet our pre-specified significance threshold it is not possible to
340 definitively *exclude* an interaction, but we report the interaction effect sizes for which we had good
341 statistical power, to demonstrate the magnitude of interactions which are unlikely to exist, given our
342 null results (**Additional file 3**). Furthermore, by focusing on selected SNVs within the known AE risk
343 loci, we acknowledge that there may be loci in which an effect is only apparent in the context of
344 interaction with an environmental exposure. These would not be detected by our analysis strategy
345 and genome-wide interaction analysis should be considered in future work if far larger sample sizes
346 than used here become available. An important limitation to this work is the use of European cohort
347 data including people of predominantly white ancestry; this reflects the current sparsity of diverse
348 ancestries in population genetic studies of sufficient size to carry out these analyses. The observed
349 differences in allele frequency of rs10214237 in African compared to European and South Asian
350 populations illustrates the limited transferability of this variant effect across population, although
351 other population-specific variants in the same locus may contribute to similar mechanistic effects.
352 International efforts are on-going to address this limitation [29], and future G*E studies are needed
353 to investigate population-specific environmental effects. More detailed sub-phenotyping of AE may,
354 in the future, reveal that more specific genetic and environmental drivers exist in distinct ancestral or
355 sub-phenotype groups.

356 In our previous systematic review focusing on gene-environment interactions with *FLG* null mutations
357 [10] we found some published evidence for *FLG**environment interactions with exposures including
358 early-life cat ownership, older siblings, water hardness, phthalate exposure, and prolonged
359 breastfeeding from the small number of previous studies. The lack of replication of *FLG**cat
360 ownership interaction in the large well-powered study reported here, and another recent meta-
361 analysis [30] represents an interesting null finding, contrasting with two small birth cohort studies
362 ([31, 32] n=379 and n=503) which reported p values for interaction <0.01 with evidence for increased
363 risks of atopic eczema in those with *FLG* null mutations exposed to cat in early life. Evidence for these
364 G*E interactions came from small numbers of individuals with *FLG* mutation, cat exposure and
365 development of atopic eczema (five people in one study [31]). We had very good power (99%) for
366 the interaction magnitude previously reported (OR_{int}=11[31]) and 80% for an interaction as small as
367 OR_{int}=1.26, suggesting very little evidence in our data for this interaction. We found little evidence for
368 *FLG**breastfeeding, consistent with our systematic review [10], where studies reported no evidence
369 for interactions with breastfeeding, although an *FLG**breastfeeding duration interaction was reported
370 from the Isle of Wight cohort [33]. Here, our post-hoc power calculation (**Additional file 3**) showed
371 adequate power (99%) for the *FLG**breastfed-ever interaction, but low power (<1%) for
372 *FLG**breastfeeding duration analyses, which may explain the discrepancy.

373 ***Conclusions***

374 We report observational evidence for an association of atopic eczema with exposure to antibiotics,
375 NO_2, and tobacco smoke in early life, but the precise nature and mechanisms of action of these
376 environmental factors on atopic skin inflammation remain unclear. We also detected an
377 observational association between early life dog exposure and reduction in prevalence of atopic
378 eczema. Further interaction analysis and functional assessments have provided evidence that dog
379 exposure reduces the genetic risk effect of rs10214237 in a pathway via *IL7R* and possibly IL-10, to
380 suppress skin inflammation. There may be an equivalent interaction effect with siblings, but this is
381 not possible to model *in vitro*. The lack of statistical evidence for other G*E explored in this analysis

382 suggests that only weak interactions are likely to exist, indicating that on a population level the
383 interactions tested and found to be null are unlikely to have important contributions to AE
384 pathogenesis. Therefore further, larger longitudinal studies should focus on alternative mechanistic
385 questions.

386 **Methods**

387 ***Aim***

388 This work aimed to investigate evidence of interaction between 24 genetic risk loci for atopic eczema
389 and 18 early-life environmental effects.

390 ***Study design and setting***

391 Genetic risk loci were defined by the 24 top hits at each locus from genome-wide association analysis
392 [11, 13] and coded for the risk-increasing allele as effect allele (**Additional file 8**). *FLG* null genotype
393 was coded as presence/absence (0/1) of any of the loss-of-function variants prevalent in the white
394 European population (R501X, 2282del4, R2447X, S3247X as previously reported [11, 34]).

395 Environmental exposures were selected on the basis of our recently published literature review [10],
396 interest from representative of a national eczema support group [12] and refined for pragmatic
397 reasons, based on data availability.

398 Genetic epidemiology and interaction analysis was used for discovery and replication. *In vitro*
399 modelling was performed to independently assess the one G*E effect that showed a nominally
400 significant interaction in the discovery and replication analyses.

401 ***Characteristics of participants***

402 **Cohort descriptions**

403 The discovery analysis included 16 population-based cohorts from people of European ancestry (N =
404 25,339) and a further 10 European population-based cohorts were included in the replication stage
405 (N = 254,532), giving a maximum total of 279,871 (maxN) in the final meta-analysis (**Additional file**
406 **1A and 1B**). Disease status was determined by either parental report or doctor diagnosis for those
407 who had “ever had eczema”. Further details on the phenotype definitions for the included studies
408 can be found in **Additional file 6**.

409

410 **Keratinocyte culture and gene expression**

411 Primary human keratinocytes were isolated from normal human skin samples excised during routine
412 surgical procedures, with patient consent, under governance of the Lothian Bioresource (reference
413 SR1665). Samples were genotyped for rs10214237 using KASP^{TM} (LGC Genomics, Teddington,
414 England). IL7R mRNA expression was quantified in 34 keratinocyte samples (3 of C:C genotype, 15 T:C
415 and 16 T:T) using RT-qPCR. RNA was isolated with TRIzol (15596026, Invitrogen, Carlsbad, USA) and
416 spin filtration columns using Direct-zol (R2072, Zymo, Irvine, USA). cDNA was prepared using
417 200ng/ml random primers (48190011, Invitrogen, Carlsbad, USA) with reverse transcriptase using
418 SuperScript IV (18090050, Invitrogen, Carlsbad, USA). qPCR was carried out using exon-spanning
419 probes (*IL7R*: HS00902334_m1, Thermo, Waltham, USA) and (*EF1A*: HS.PT.58.24345862, Integrated
420 DNA Technologies ,San Diego, USA) with TaqMan Universal Master Mix II (4440040, Thermo,
421 Waltham, USA) and run on a CFX384 PCR Detection System (Bio-Rad, Hercules, USA) using cycling
422 conditions: 95°C for 10 mins, 40 cycles of [95°C for 15 secs, 60°C for 1 min]. Fold changes in gene
423 expression were derived via the 2(-Delta Delta C[T]) method, using *EF1A* as the reference gene.

424 ***In vitro* analysis for rs10214237*dog interaction**

425 To investigate the effect of dog allergen on human keratinocytes, monolayers were treated for 8h
426 with 10ug/ml dog allergen (Can f 1, catalogue E802, Immunotek, Madrid, Spain). RNA isolation and
427 RT-qPCR were carried out as above (*CXCL8*: Hs.PT.58.38869678.g, *CSF2*: Hs.PT.58.20138984, *CCL2*:
428 Hs.PT.58.45467977, *TNF*: Hs.PT.58.45380900, *IL33*: Hs.PT.58.21416460, *EF1A*: HS.PT.58.24345862,
429 Integrated DNA Technologies, San Diego, USA) and (*TSLP*: Hs00263639_m1, Thermo, Waltham, USA).
430 Experiments were replicated using keratinocytes from 5-12 independent donors.

431 To investigate a genotype-specific effect of IL-7 and/or dog allergen stimulation, keratinocytes were
432 grown to confluency and treated with 100ng/ml recombinant human IL-7 (rhIL-7) (BioTechne,
433 Minneapolis, USA, catalogue: 207-IL) and 500ng/ml Dog dander (Lofarma, Milan, Italy) for 8 hours.

434 The carrier solution for dog dander (Lofarma) or 0.002% BSA, used as a carrier protein for rhIL-7 were
435 negative controls and experiments were conducted in duplicate for each condition.

436 One-way analysis of variance (ANOVA) with Dunnett's post-hoc test for multiple comparisons was
437 used to compare samples' means and results displayed showing standard error of the mean (SEM).

438 Gene ontology, network and pathway analyses were conducted using STRING v12.0.

439 ***Statistical genetic analysis***

440 The early-life environmental exposures for investigation included pet ownership for cat and dog
441 separately, house dust mite exposure, washing practices (to represent environmental irritants),
442 cigarette tobacco smoking within the household, antibiotic use, environmental pollution, breast
443 feeding mode of delivery and presence of older siblings. These are listed in **Additional file 7**, with
444 details of their definition and coding. The exposures were tested for interaction effects with 24 SNPs
445 previously reported for eczema risk [11, 35] (**Additional file 8**). This involved fitting a statistical model
446 to include the main effect of the SNP upon eczema (G) (extracted from Paternoster et al, 2015[11]),
447 the main effect of the environmental factors upon eczema (E), and the product of the SNP effect and
448 the environmental effect (G*E). Logistic regression models were applied to identify the main effect of
449 each environmental factor (models M1 to M4, **Additional file 9**), and to test for interaction between
450 the exposure and each SNP while adjusting for sex (models I1 to I3, **Additional file 9**). Sensitivity
451 analyses were also performed while adjusting for family history of atopic disease (asthma, eczema or
452 hay fever) and parental education as a proxy for socioeconomic status (models S1 to S3, **Additional**
453 **file 9**).

454 Analyses were performed separately within each cohort and then combined by performing fixed-
455 effects meta-analyses. Genetic data was imputed separately for each cohort. Further imputation
456 details can be found in the **Additional file 6**.

457 ***Power calculation***

458 Posthoc estimates of statistical power were calculated in Quanto (version 1.2.4). These were
459 informed by effect size estimates from the discovery analyses or previously published studies,
460 assuming case-to-control ratio of 1:3, and alpha=0.004 in replication analyses (0.05/14 for multiple
461 testing of 14 gene-environment pairs) (**Additional file 3**).

462

463 **Abbreviations**

464 ANOVA	Analysis of variance
465 *FLG*	Gene encoding filaggrin
466 G*E	Gene-environment interaction
467 GWAS	Genome-wide association study
468 maxN	Maximum number of individuals in the analysis
469 OR	Odds ratio
470 SEM	Standard error of mean
471 SNV	Single nucleotide variant
472 TSLP	Thymic stromal lymphopoietin

Declarations

Ethics approval and consent to participate

Each contributing cohort has ethical approval for the sharing of anonymised data from study participants, with their written informed consent.

Consent for publication

The named authors provide consent for publication of this work.

Availability of data and materials

All results supporting the conclusions of this article are included within manuscript and Additional files. Specifically, full results for all the models tested are given in **Additional files 2 and 10**. Each cohort contributing to the analysis has their own controlled-access procedures and should be contacted directly to obtain access to individual level data.

Competing interests

SJB has received research funding (but no personal financial benefits) from the Wellcome Trust (220875/Z/20/Z), UKRI, Medical Research Council, Rosetrees Trust, Stoneygates Trust, British Skin Foundation, Charles Wolfson Charitable Trust, anonymous donations from people with eczema, Unilever, Pfizer, Abbvie, Sosei-Heptares, Janssen, European Lead Factory (which includes multiple industry partners). SJB, AB-A, KB, ADI, GHK, CS, SML and LP have received funding from the BIOMAP-IMI consortium (EU H2020 project ref No 821511) which receives support from several pharmaceutical industry partners. LP has received honorarium payment for a scientific talk on eczema genetics from LEO Pharma.

GHK reports grants from the Netherlands Lung Foundation, ZON-MW, Ubbo Emmius Foundation, TEVA the Netherlands, GSK, Vertex, outside the submitted work (money to institution). His institution received compensation for consultancy or lectures from Astra Zeneca, Boehringer Ingelheim and Sanofi.

Funding

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821511(BIOMAP). The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This publication/dissemination reflects only the author's view and the JU is not responsible for any use that may be made of the information it contains. M.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant Agreement No. 949906). NJR's research/laboratory is funded in part by the Newcastle NIHR Biomedical Research Centre (BRC), the Newcastle NIHR Medtech and In vitro diagnostics Co-operative and the NIHR Newcastle Patient Safety Research Collaboration and NJR is a NIHR Senior Investigator. LP has received funding from a MRC Population Health Scientist Fellowship (MR/J012165/1) and receives support from the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/1, MC_UU_00032/01). SJB holds a Wellcome Trust Senior Research Fellowship (220875/Z/20/Z). The MAS study up to adolescence was funded by several grants from the German Federal Ministry of Education and Research (07015633, 07 ALE 27, 01EE9405/5, and 01EE9406). EHL was supported by a fellowship awarded by MCIN/AEI/10.13039/501100011033 and by "ESF Investing in your future" [PRE2018-083837]. MAAS was supported by the Asthma UK Grants No 301 (1995-1998), No 362 (1998-2001), No 01/012 (2001-2004), No 04/014 (2004-2007), BMA James Trust (2005) and The JP Moulton Charitable Foundation (2004-current), The North west Lung Centre Charity (1997-current) and the Medical Research Council (MRC) G0601361 (2007-2012), MR/K002449/1 (2013-2014) and MR/L012693/1 (2014-2018), and MR/S025340/1 UNICORN (Unified Cohorts Research Network): Disaggregating asthma (2020-2024). This study was delivered through the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The PIAMA study has been supported by project grants from the Netherlands Organization for Health Research and Development; the Netherlands

Organization for Scientific Research; the Lung Foundation Netherlands (formerly Netherlands Asthma Fund); the Netherlands Ministry of Spatial Planning, Housing, and the Environment; and the Netherlands Ministry of Health, Welfare, and Sport.

Authors' contributions

AB-A, PB, KB, DB, SJB, MBP, ACu, CF, JHe, JWH, JO'BH, ADI, GK, PdM, SML, Y-AL, DM, EM, CSM, DMM, SP, LP, CP, NJR, AS, CS, MS, JPT and CW made substantial contributions to the conception or design of the work; all authors contributed to the acquisition, analysis, or interpretation of data; AB-A, SJB, ACu, LD, CF, ADI, GK, SML, Y-AL, LP, NJR, CS and MS drafted the work or substantively revised it.

All authors have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Acknowledgements

We are grateful to all patients and participants in the contributing cohort studies and to the skin donors and surgical team at the Western General Hospital, Edinburgh, for providing samples of normal skin tissue for this research; to our UK-TREND collaborators including Mike Cork for informative discussion; to Heather J Cordell for advice on statistical genetics approaches; to Lisa Maier for preparing **Figure 1;** and to Dr Lauren Kelly and Ms Lucy Glass for administrative support.

Authors' information

MS, AB-A, LP are experts in statistical genetic analysis of complex traits including AE; SML is a clinical academic dermatologist with epidemiology expertise; SJB is a clinical academic dermatologist with expertise in genetic epidemiology and functional genetics. NJR is a clinical academic dermatologist with expertise in immune mediated inflammatory skin disorders and precision medicine.

References

1. Johansson S, Bieber T, Dahl R, Friedmann P, Lanier B, Lockey R, Motala C, Ortega Martell J, Platts-Mills T, Ring J, et al: **Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.** *J Allergy Clin Immunol* 2004, **113:**832-836.

2. Mehrmal S, Uppal P, Giesey RL, Delost GR: **Identifying the prevalence and disability-adjusted life years of the most common dermatoses worldwide.** *J Am Acad Dermatol* 2020, **82:**258-259.

3. Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Nedley N, Delost GR: **The global, regional, and national burden of atopic dermatitis in 195 countries and territories: An ecological study from the Global Burden of Disease Study 2017.** *JAAD Int* 2021, **2:**12-18.

4. Langan SM, Irvine AD, Weidinger S: **Atopic dermatitis.** *Lancet* 2020, **396:**345-360.

5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS: **Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.** *J Allergy Clin Immunol* 2009, **124:**1251-1258 e1223.

6. Genuneit J, Seibold AM, Apfelbacher CJ, Konstantinou GN, Koplin JJ, La Grutta S, Logan K, Perkin MR, Flohr C, Task Force 'Overview of Systematic Reviews in Allergy Epidemiology ' of the EIGoE: **Overview of systematic reviews in allergy epidemiology.** *Allergy* 2017, **72:**849-856.

7. Rutter CE, Silverwood RJ, Williams HC, Ellwood P, Asher I, Garcia-Marcos L, Strachan DP, Pearce N, Langan SM, Group IPTS: **Are Environmental Factors for Atopic Eczema in ISAAC Phase Three due to Reverse Causation?** *J Invest Dermatol* 2018.

8. Brown SJ: **What Have We Learned from GWAS for Atopic Dermatitis?** *J Invest Dermatol* 2021, **141:**19-22.

9. Ottman R: **Gene-environment interaction: definitions and study designs.** *Prev Med* 1996, **25:**764-770.

569 10. Blakeway H, Van-de-Velde V, Allen VB, Kravvas G, Palla L, Page MJ, Flohr C, Weller RB, Irvine AD,
570 McPherson T, et al: **What is the evidence for interactions between filaggrin null mutations and**
571 **environmental exposures in the aetiology of atopic dermatitis? - A systematic review.** *Br J Dermatol*
572 2019.

573 11. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, Curtin JA, Bonnelykke K, Tian C,
574 Takahashi A, et al: **Multi-ancestry genome-wide association study of 21,000 cases and 95,000**
575 **controls identifies new risk loci for atopic dermatitis.** *Nat Genet* 2015, **47:**1449-1456.

576 12. Brown SJ: **Discussion with Eczema Outreach Scotand** 2018.

577 13. Budu-Aggrey A, Kilanowski A: **European and multi-ancestry genome-wide association meta-analysis**
578 **of atopic dermatitis highlights importance of systemic immune regulation.** *Nat Commun* 2023, **in**
579 **press**.

580 14. Sobczyk MK, Richardson TG, Zuber V, Min JL, Gaunt TR, Paternoster L, eQtlgen Consortium BCG:
581 **Triangulating Molecular Evidence to Prioritize Candidate Causal Genes at Established Atopic**
582 **Dermatitis Loci.** *J Invest Dermatol* 2021, **141:**2620-2629.

583 15. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Bjork L, Breckels
584 LM, et al: **A subcellular map of the human proteome.** *Science* 2017, **356**.

585 16. **Human Protein Atlas available from http://www.proteinatlas.org**

586 17. Patel G, Saltoun C: **Skin testing in allergy.** *Allergy Asthma Proc* 2019, **40:**366-368.

587 18. Boyman O, Werfel T, Akdis CA: **The suppressive role of IL-10 in contact and atopic dermatitis.** *J Allergy*
588 *Clin Immunol* 2012, **129:**160-161.

589 19. Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Fujimura T, Aiba S, Nakayama K,
590 Okuyama R, Yamamoto M: **The aryl hydrocarbon receptor AhR links atopic dermatitis and air**
591 **pollution via induction of the neurotrophic factor artemin.** *Nat Immunol* 2017, **18:**64-73.

592 20. Luschkova D, Zeiser K, Ludwig A, Traidl-Hoffmann C: **Atopic eczema is an environmental disease.**
593 *Allergol Select* 2021, **5:**244-250.

594 21. Zhong W, Wu X, Zhang W, Zhang J, Chen X, Chen S, Huang H, Yang Y, Yu B, Dou X: **Aberrant Expression**
595 **of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the**
596 **Pathogenesis of Prurigo Nodularis.** *Acta Derm Venereol* 2019, **99:**579-586.

597 22. Ebina-Shibuya R, Leonard WJ: **Role of thymic stromal lymphopoietin in allergy and beyond.** *Nat Rev*
598 *Immunol* 2023, **23:**24-37.

599 23. Liew FY, Girard JP, Turnquist HR: **Interleukin-33 in health and disease.** *Nat Rev Immunol* 2016, **16:**676-
600 689.

601 24. Thorsteinsdottir S, Thyssen JP, Stokholm J, Vissing NH, Waage J, Bisgaard H: **Domestic dog exposure at**
602 **birth reduces the incidence of atopic dermatitis.** *Allergy* 2016, **71:**1736-1744.

603 25. Eapen AA, Sitarik AR, Cheema G, Kim H, Ownby D, Johnson CC, Zoratti E: **Effect of prenatal dog**
604 **exposure on eczema development in early and late childhood.** *J Allergy Clin Immunol Pract* 2022,
605 **10:**3312-3314 e3311.

606 26. Tutino M, Granell R, Curtin JA, Haider S, Fontanella S, Murray CS, Roberts G, Arshad SH, Turner S,
607 Morris AP, et al: **Dog ownership in infancy is protective for persistent wheeze in 17q21 asthma-risk**
608 **carriers.** *J Allergy Clin Immunol* 2023, **151:**423-430.

609 27. Lehtimaki J, Sinkko H, Hielm-Bjorkman A, Laatikainen T, Ruokolainen L, Lohi H: **Simultaneous allergic**
610 **traits in dogs and their owners are associated with living environment, lifestyle and microbial**
611 **exposures.** *Sci Rep* 2020, **10:**21954.

612 28. Shungin D, Deng WQ, Varga TV, Luan J, Mihailov E, Metspalu A, Consortium G, Morris AP, Forouhi NG,
613 Lindgren C, et al: **Ranking and characterization of established BMI and lipid associated loci as**
614 **candidates for gene-environment interactions.** *PLoS Genet* 2017, **13:**e1006812.

615 29. Borrell LN, Elhawary JR, Fuentes-Afflick E, Witonsky J, Bhakta N, Wu AHB, Bibbins-Domingo K,
616 Rodriguez-Santana JR, Lenoir MA, Gavin JR, 3rd, et al: **Race and Genetic Ancestry in Medicine - A**
617 **Time for Reckoning with Racism.** *N Engl J Med* 2021, **384:**474-480.

618 30. Thyssen JP, Ahluwalia TS, Paternoster L, Ballardini N, Bergstrom A, Melen E, Chawes BL, Stokholm J,
619 Hourihane JO, O'Sullivan DM, et al: **Interaction between filaggrin mutations and neonatal cat**
620 **exposure in atopic dermatitis.** *Allergy* 2020, **75:**1481-1485.

621 31. Bisgaard H, Simpson A, Palmer CN, Bonnelykke K, McLean I, Mukhopadhyay S, Pipper CB, Halkjaer LB,
622 Lipworth B, Hankinson J, et al: **Gene-environment interaction in the onset of eczema in infancy:**
623 **filaggrin loss-of-function mutations enhanced by neonatal cat exposure.** *PLoS Med* 2008, **5:**e131.

624 32. Schuttelaar ML, Kerkhof M, Jonkman MF, Koppelman GH, Brunekreef B, de Jongste JC, Wijga A,
625 McLean WH, Postma DS: **Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever**
626 **and the interaction with cat exposure.** *Allergy* 2009, **64:**1758-1765.

627 33. Ziyab AH, Mukherjee N, Ewart S, Arshad SH, Karmaus W, Turati F, Bertuccio P, Galeone C, Pelucchi C,
628 Naldi L, et al: **Filaggrin gene loss-of-function variants modify the effect of breast-feeding on eczema**
629 **risk in early childhood.** *Allergy* 2016, **71:**1371-1373.

630 34. Sandilands A, Terron-Kwiatkowski A, Hull P, O'Regan G, Clayton T, Watson R, Carrick T, Evans A, Liao H,
631 Zhao Y, et al: **Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare**
632 **mutations in ichthyosis vulgaris and atopic eczema.** *Nat Genet* 2007, **39:**650-654.

633 35. Budu-Aggrey A, Kilanowski A, Sobczyk MK, andMe Research T, Shringarpure SS, Mitchell R, Reis K,
634 Reigo A, Estonian Biobank Research T, Magi R, et al: **European and multi-ancestry genome-wide**
635 **association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation.**
636 *Nat Commun* 2023, **14:**6172.

637

638

Figures and Table



Figure 1. Heatmap to summarise results of interaction analyses

Strength of colour indicates beta in which blue is positive and red is a negative direction of effect; diameter of circle indicates sample size; 14 nominally significant interactions (p_{int}<0.05) are highlighted with black outline; one association was reported in only one cohort, so was not pursued further.

Figure 2a: Unexposed stratum



Figure 2b: Exposed stratum



Figure 2. Forest plot showing interaction of dog exposure with rs1041237 in exposed and unexposed strata

Interaction analysis for discovery (N=18,045), replication (N=47,185) and combined meta-analysis (total N= 65,230) show the T allele of rs1041237 increases risk of atopic eczema only amongst those who are not exposed to a dog in the family home. Full names and study cohort descriptions are given in **Additional file 6**.



652

653 **Figure 3. *In vitro* testing of the effects of dog allergen on primary human keratinocytes.**

654 **(3A)** Dog allergen exposure stimulated a reduction in *IL33* and *TSLP* mRNA but upregulation of *CXCL8* (IL-8),
655 *CSF2*, *CCL2* and *TNF*; negative indicates keratinocyte media with dog allergen carrier solution; 5-12 donor
656 isolates shown, bars represent SEM one-way ANOVA, Dunnet post hoc test compared to negative control,
657 **p<0.01, ***p<0.001 ****p<0.0001. **(3B)** IL-10 signalling was the most significantly enriched Reactome
658 pathway (4 out of 45 genes/proteins, FDR 7.71e-08). **(3C-3E)** Effects of IL-7 and dog allergen stimulation on
659 primary human keratinocytes with different rs10214237 genotypes in which T is eczema risk allele; graphs
660 represent the mean fold change in cytokine mRNA expression relative to the housekeeping gene *EF1A*, from 4
661 keratinocyte isolates with T:T genotype and 2 keratinocyte isolates from donors of C:C genotype; untreated
662 indicates keratinocyte media only and negative is keratinocyte media with dog allergen carrier solution; BSA as
663 0.0002% included for as carrier protein for recombinant Il-7; two-way ANOVA with Dunnett's post-hoc test,
664 compared to the negative control, bars represent SEM, *p<0.05, **p<0.01.

Exposure	SNV or gene	Discovery							Replication					p-value combined
		N	N studies	OR	95% CI	p-value	p-value random	p-value heterogeneity	N	N studies	OR	95% CI	p-value	
Antibiotic use in utero	rs10995251	11575	7	1.19	[1.00-1.42]	0.045	0.059	0.34	2666	1	0.88	[0.55-1.41]	0.59	0.09
Cat ownership	rs16948048	14063	10	0.86	[0.76-0.97]	0.012	0.29	0.054	49212	3	1	[0.92-1.08]	0.98	0.17
Cat ownership	rs2227483	14644	11	1.13	[1.01-1.27]	0.037	0.18	0.014	49212	3	1.05	[0.97-1.13]	0.25	0.036
Cat ownership	rs2228145	12994	9	1.14	[1.01-1.29]	0.037	0.037	0.61	49212	3	1	[0.92-1.08]	0.93	0.3
Cat ownership	rs2897442	12702	9	0.87	[0.75-1.00]	0.044	0.11	0.35	49212	3	1.02	[0.94-1.11]	0.59	0.58
Dog ownership	rs10214237	14656	11	0.83	[0.72-0.96]	0.011	0.014	0.37	47185	2	0.91	[0.83-0.99]	0.025	0.0013
Duration of any breastfeeding	rs13015714	14474	9	1.02	[1.00-1.03]	0.049	0.068	0.32	4252	5	0.99	[0.95-1.02]	0.47	0.14
Elder siblings	rs10214237	19155	11	0.84	[0.75-0.94]	0.003	0.003	0.99	5049	4	1.09	[0.82-1.46]	0.55	0.011
Elder siblings	rs10995251	18608	10	0.89	[0.80-1.00]	0.042	0.042	0.44	7529	6	1.03	[0.85-1.25]	0.74	0.11
Elder siblings	rs7146581	19176	11	1.25	[1.10-1.42]	0.00042	0.0031	0.32	7529	6	1.04	[0.84-1.29]	0.73	0.0012
Elder siblings	rs7927894	18263	10	1.13	[1.01-1.26]	0.031	0.031	0.53	7529	6	1	[0.83-1.21]	0.97	0.058
Smoking in household up to 2 years	*FLG**	15618	12	1.33	[1.05-1.68]	0.018	0.022	0.36	147880	7	1.01	[0.81-1.25]	0.93	0.096
Smoking in household in utero	rs16948048	16062	11	1.15	[1.02-1.31]	0.028	0.028	0.53	8078	5	1.04	[0.85-1.27]	0.72	0.039
Washing practices up to 2 years	*FLG**	6962	3	0.71	[0.51-0.99]	0.045	0.12	0.31	1061	1	1.93	[0.29-12.99]	0.5	0.063

Table 1. Nominally significant interaction results from discovery and replication analyses

Results of testing for interaction between 24 genetic variants and 18 environmental exposures; *combined null genotype for 2 or more loss-of-function mutations in *FLG* as detailed in cohort descriptions (**Additional file 6**); nominal significance defined as unadjusted $p_{int}<0.05$. N, number; OR, odds ratio; p-value indicates significance from fixed effects meta-analysis; p-value random indicates significance from random effects meta-analysis; p-value combined indicates significance from combined fixed effects meta-analysis of discovery and replication data.

671 **List of additional Files**

672 **Additional file 1. List of cohorts and available exposure data**

673 **1A**. Included cohorts and exposure availability at discovery stage.

674 **1B**. Included cohorts and exposure availability at replication stage.

675 **Additional file 2. Full results of the discovery analysis**

676 Exposure, environmental exposure; N, number of individuals; N_studies, number of studies;
677 OR_fixed, odds ratio from fixed effect.

678 **Additional file 3. Estimation of statistical power**

679 Posthoc power calculations performed to facilitate interpretation of negative findings.

680 **Additional file 4. *IL7R* mRNA expression in cells of different rs10214237 genotype**

681 Rs10214237 T:T genotype is associated with higher expression level of *IL7R* mRNA than C:C
682 genotype; **4A** and **4B**, Screenshots from GTEx Portal
683 (https://www.gtexportal.org/home/snp/rs10214237 accessed 14/04/2024) showing T:T genotype is
684 associated with higher *IL7R* mRNA expression in cultured fibroblasts and whole blood; **4C**, shows
685 higher mRNA expression levels in primary human keratinocytes of T:T than C:C genotype.

686 **Additional file 5. Results of cytokine, chemokine and receptor expression on human primary**
687 **keratinocytes following dog allergen exposure**

688 **5A.** Protein detection by ELISA.

689 **5B.** STRING network analysis of upregulated genes.

690 **5C.** Cytokine expression from primary human keratinocytes.

691 **5D.** STRING network analysis of genes showing no significant change in expression.

692 **Additional file 6. Supplementary methods**

693 **Additional file 7. Definition and coding of environmental exposures**

694 **Additional file 8. Table of selected SNVs, risk alleles and risk allele frequencies**

695 **Additional file 9. Logistic regression models on ever having atopic eczema**

696 **Additional file 10. Full results of the replication analysis**

697 Exposure, environmental exposure; N, number of individuals; N_studies, number of studies;
698 OR_fixed, odds ratio from fixed effect meta-analysis; CI_fixed, 95%-confidence interval from fixed
699 effect meta-analysis; p_fixed, p-value from fixed effect meta-analysis; OR_random, odds ratio from
700 random effects meta-analysis; CI_random, 95%-confidence interval from random effects meta-
701 analysis; p_random, p-value from random effects meta-analysis; p_heterogeneity, p-value from Q-
702 statistic.